Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed stage I (T\>1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy~* The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in ≤ 10% of invasive cancer cells by Immunohistochemistry.~* HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing~* No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer~* Female subjects age 18 - 70 years~* ECOG Performance Status of 0-1~* Adequate organ and marrow function as defined below:~  * Leukocytes ≥ 3,000/uL~ * Absolute neutrophil count ≥ 1500/uL~ * Platelets ≥ 100,000/uL~ * Total bilirubin ≤ 1.5mg/dL~ * AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal~ * Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min~ * Serum albumin ≥ 3.0 g/dL~* Women of child-bearing potential must agree to use adequate contraception~* Pretreatment lab values must be performed within 14 days of treatment initiation, and other baseline studies performed within 30 days prior to registration~* Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4 weeks prior to treatment initiation~* Subjects should have breast and axillary imaging with breast MRI or breast and axillary ultrasound within 4 weeks prior to treatment initiation~* Subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy/fine needle aspiration.~* Subjects must be already enrolled in P.R.O.G.E.C.T observational registry~* Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease~* Subjects with bilateral disease are eligible if they meet other eligibility criteria.~* Neuropathy: No baseline neuropathy grade \> 2~Exclusion Criteria:~* Current or anticipated use of other investigational agents~* Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer~* Subject with metastatic disease~* History of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study~* Subjects with inflammatory breast cancer~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements~* Subject is pregnant or nursing~* Subjects with concomitant or previous malignancies within the last 5 years. Exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS).~* Ejection Fraction \<50% on ECHO or MUGA~* Cardiac function: Subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP\>160 or Diastolic BP\>90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral vascular disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide (Type: ACTIVE_COMPARATOR): Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
- Carboplatin + Docetaxel (Type: ACTIVE_COMPARATOR): Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).